These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7919137)

  • 1. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy.
    Kaupke CJ; Kim S; Vaziri ND
    J Am Soc Nephrol; 1994 May; 4(11):1874-8. PubMed ID: 7919137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron metabolism under rEPO therapy in patients on maintenance hemodialysis.
    Bergmann M; Grützmacher P; Heuser J; Kaltwasser JP
    Int J Artif Organs; 1990 Feb; 13(2):109-12. PubMed ID: 2347653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of recombinant human erythropoietin (rEPO) on angina pectoris in patients with chronic maintenance hemodialysis].
    Imamura Y; Hase H
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):403-8. PubMed ID: 1875559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.
    Levin NW; Lazarus JM; Nissenson AR
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):3-12. PubMed ID: 8352269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
    Eschbach JW; Abdulhadi MH; Browne JK; Delano BG; Downing MR; Egrie JC; Evans RW; Friedman EA; Graber SE; Haley NR
    Ann Intern Med; 1989 Dec; 111(12):992-1000. PubMed ID: 2688507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
    Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
    Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].
    Müller R; Steffen HM; Brunner R; Pollok M; Baldamus CA; Kaufmann W
    Klin Wochenschr; 1991 Oct; 69(16):742-8. PubMed ID: 1662322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
    Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
    Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
    Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
    Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
    Walter J; Gål J; Taraba I
    Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.